The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. Nor can there be any guarantee that such products will be commercially successful in the future. About Sandoz.

Clinical Development 52

Clinical Development Medicine Development Containment 52

The Pharma Data

MAY 18, 2021

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. Nor can there be any guarantee that such products will be commercially successful in the future. About Sandoz.

Manufacturing 40

Manufacturing Production Containment Generic Pharmaceutical 40

The Pharma Data

MAY 2, 2021

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. Nor can there be any guarantee that such products will be commercially successful in the future. About Sandoz.

Clinical Development 40

Clinical Development Medicine Development Production 40

The Pharma Data

MAY 15, 2023

Find out more at [link] About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. Nor can there be any guarantee that such products will be commercially successful in the future.

Sales 40

Sales Production Doctors Doctor 40

Pharmaceutical Technology

SEPTEMBER 22, 2022

The OA space is characterised by a high level of unmet clinical need driven by the limited effectiveness of currently available analgesics and the lack of disease-modifying OA drugs (DMOADs). Within the OA late-stage pipeline, there are two cell-based therapies that GlobalData believes have significant clinical and commercial potential.

Marketing 147

Marketing Generic Pharmaceutical Clinical Trials Clinical Trials 147

XTalks

AUGUST 2, 2023

Clinical trials have shown that the vaccine is 90 percent effective in preventing shingles for individuals aged 50 and over. 2) Xevudy (sotrovimab) Xevudy, a monoclonal antibody treatment for SARS-CoV-2, generated £2.31 Teva Pharmaceutical Industries Ltd. It is one of the largest generic drug manufacturers in the world.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

DECEMBER 23, 2020

24, 2020 /PRNewswire/ — COVAXX’s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate. .

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

The Pharma Data

DECEMBER 23, 2020

COVAXX is currently completing a Phase 1 clinical trial of UB-612 in Taiwan and will begin Phase 2/3 clinical trials in Asia, Latin America and the U.S. This agreement is in addition to the recently announced advanced purchase commitments of more than 140 million doses of COVAXX’s UB-612 vaccine, totaling over $2.8

Vaccination 52

Vaccination Vaccine Manufacturing Antibody 52

Pharmaceutical Technology

MARCH 22, 2023

In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. This will enable them to expand their clinical trial supplies and logistics offerings, and expand networks for on-time delivery of supplies and drugs.

Production 263

Production Manufacturing Generic Drugs Drugs 263